Gilead Sciences, Inc.
NEWS
A study published in the journal Nature on July 1 suggests that there may be a new way to target an HIV protein called capsid, which was almost unmanageable in patients until now.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
Gilead Sciences set the price of the only approved treatment for COVID-19, remdesivir, at $390 per vial, which for most patients receiving a 5-day treatment using six vials, would come to $2,340 per patient.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 29, 2020.
It was a busy week for clinical trial updates. Here’s a look.
Today, Gilead announced that it was acquiring a 49.9% equity interest in Pionyr Immunotherapeutics for $275 million and exclusive option to buy the rest of the company.
In an open letter from the company’s chairman and chief executive officer, Daniel O’Day reported that the U.S. Food and Drug Administration (FDA) had given the company approval to begin clinical trials of an inhaled version of the drug.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 22, 2020.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 19, 2020.
JOBS
IN THE PRESS